Creso Pharma Limited to announce that over 100,000 dogs are estimated to have benefited from the Company's anibidiol® range of hemp oil complementary feed products. This milestone corresponds to over 3 million portion sachets of anibidiol® granules used as complementary feed to help mitigate stress and improve wellbeing in dogs. Creso Pharma developed anibidiol® and patented its granulated delivery system. It is produced in Switzerland and is commercialised in collaboration with Virbac S.A. in more than 10 countries in Europe. Its global sales grew approximately 700% in 2019. anibidiol® Regular and anibidiol® Plus are commercialised for small, medium-sized and large pets to support the reduction of stress and aid in the functioning of the animals' nervous systems. Pet owners report anibidiol® has also contributed to the management of pain and improved the vitality of their pets after one week of use in addition to normal feed. Creso Pharma has successfully developed 3 additional hemp-derived products to improve the wellbeing of pets, which are slated for launch during 2020. Together with Virbac Switzerland, the Company recently launched its new anibidiol® Oil 500 product as a lifecycle management enhancement for the anibidiol® range, responding to strong demand from veterinaries and pet owners. Initially the product will be marketed in Switzerland, with other national markets being added throughout 2020.